PDS Biotechnology Corp (PDSB)

[Fress]

CEORoadshow Interview with Dr. Frank Bedu-Addo, President & CEO of PDS Biotechnology (PDSB)

PDS Biotech preparing to initiate 3 phase 2 clinical studies for lead candidate PDS0101

Clinical testing of PDS Biotech’s Versamune®-based COVID-19
vaccine candidates PDS203 & PDS204 is ongoing with a clear target profile:

1.Induction of highly-potent, SARS-CoV-2-specific killer 1 T-cells
2.Demonstrate high levels of both SARS-CoV-2-specific 2 T-cell and antibody response after a single dose
3.Poised for rapid commercial scale up
4.No safety signals

$PDSB